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ABSTRACT 
 
Administering high-dose chemotherapy (HDCT) with melphalan to elderly myeloma 
patients represents a challenge with respect to achieving therapeutic efficacy whilst 
avoiding significant toxicity. We analyzed safety and efficacy of HDCT in 61 elderly 
myeloma patients older than 65 years, including 12 patients ≥70 years, and 
compared them to 237 MM patients below 65 years treated in the same period. MM 
patients older than 70 years had a longer duration of hospitalization (26 vs. 20 days; 
P=.0001) and a longer time until platelet recovery >20 G/L (19 vs. 15 days; 
P=.0398). However, we observed no differences in the time until neutrophil recovery, 
infection rate, and treatment related mortality until 100 days after ASCT. 
Furthermore, higher age was not associated with inferior progression-free and 
overall survival at 1 and 2 years after ASCT. Our data suggest that HDCT with ASCT 
is feasible, safe and effective in MM patients older than 65 years. 
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INTRODUCTION 
 
Symptomatic multiple myeloma (MM) is a malignant plasma cell disease 
characterized by the presence of a specific monoclonal immunoglobulin and related 
organ damages including hypercalcemia, renal insufficiency, anemia, or lytic bone 
lesions (CRAB) [1,2]. Most symptomatic MM patients are elderly, defined as being 
older than 65 years of age, with the incidence of MM increasing along the aging of 
the general population and its increasing life expectancy. 
Since the late 1990s, high-dose melphalan treatment (200mg/m2) followed by 
autologous stem cell transplantation (ASCT) has been regarded as a standard 
procedure for younger MM patients in the absence of relevant comorbidities [3-5]. In 
the first decade of the 21st century, bortezomib-based regimens have become 
standard induction therapy preceding ASCT in transplant-eligible patients and have 
additionally contributed to improved survival for younger MM patients [6-10]. 
However, the significant improvement in overall survival has mainly been observed 
in younger MM patients [11-17], whereas advances for elderly MM patients have 
been less significant [11,14,16,18].  
MM patients aged older than 65 years are usually considered as ineligible for high-
dose melphalan therapy (200mg/m2) followed by ASCT mainly because of 
impairment in organ functions and reduced drug metabolisms. Consequently, clinical 
trials involving ASCT have mostly been restricted to patients younger than 65 years 
with few exceptions. The toxicity of 200mg/m2 high-dose melphalan was 
investigated in 25 elderly patients aged 70 years or older [19] resulting in four (16%) 
transplant-related deaths (TRM), but after reducing the dose to 140mg/m2 the TRM 
could be reduced to 2% while maintaining the efficacy. Of crucial importance was a 
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subsequent trial with 2-3 courses of ASCT with 100mg/m2 of melphalan in 71 
patients aged up to 75 years [20]. When compared with matched-pair patients 
treated with melphalan and prednison (MP), the efficacy of ASCT was significantly 
superior to MP in terms of complete response (CR) rate, event-free survival (EFS) 
and OS, without transplant-related deaths. Based on these reports, elderly patients 
with MM in otherwise fit medical condition have been considered to be eligible for 
ASCT irrespective of the chronological age in many institutions [21,22]. Accordingly, 
several single institution studies have reported their experience of ASCT in elderly 
patients [23-30]. As conditioning regimen before ASCT, reduced dosing of melphalan 
(100–140mg/m2) has been predominantly used in elderly patients, with no significant 
difference in transplant-related mortality and morbidity between elderly and younger 
patients. Recently, the transplant-related mortality in MM patients has decreased to 
2-4%, probably due to the improvement of supportive therapies [31]. As a 
consequence, reduced-intensity ASCT is considered to be a safe and effective 
therapeutic modality even in MM patients aged 65-75 years in a good performance 
status without relevant comorbidities. Accordingly, physicians increasingly tend to 
raise the upper age limit, and a substantial number of elderly MM patients is offered 
ASCT in clinical routine nowadays.  
In order to further evaluate the safety and efficacy of ASCT in this cohort of patients, 
we performed a retrospective analysis of data obtained from elderly MM patients 
aged older than 65 years at our center. We compared these results with data 
obtained from MM patients younger than 66 years of age treated in the same period 
to assess the toxicity and the survival benefit of HDCT with ASCT in elderly MM 
patients. 
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MATERIAL AND METHODS 
 
Patients: Patients with MM consecutively seen at the University Hospital of Bern, 
Switzerland from January 2009 to May 2015 who received at least one HDCT with 
ASCT were studied. All patients had given written informed consent, and this study 
was approved by the local ethics committee of Bern, Switzerland (decision number 
#149-14). The patients were stratified into three groups according to their age at 
ASCT. Group 1 comprised MM patients aged 18-65 years, group 2 involved MM 
patients aged 66-69 years, and MM patients in group 3 were ≥70 years.  
 
Treatment 
According to local standards, non-myelosuppressive chemotherapy with vinorelbine 
or gemcitabine, but not cyclophosphamide, together with G-CSF was used for 
mobilization of autologous stem and progenitor cells [32-34]. At least 3x106 CD34+ 
cells/kg body weight (b.w.) were collected per planned stem cell transplantation. 
Patients above 70 years received a reduced dose of melphalan (140mg/m2), 
whereas patients ≤70 years were administered full dose melphalan (200mg/m2); the 
dose of melphalan was reduced to 140 mg/m2 for patients with reduced renal 
function with a creatinine-clearance between 40-50ml/min, and to 100mg/m2 for 
patients with a creatinine-clearance below 40ml/min. All patients received weight 
adapted G-CSF starting at day 6 after ASCT until neutrophils exceeded 0.5 G/L for 
three consecutive days. Patients routinely had antiviral (acyclovir 500mg twice daily) 
and antifungal prophylaxis (fluconazole 400mg once weekly and 
sulfamethoxazol/trimethoprim 800/160mg three times per week). 
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Definitions  
Objectives of the study with regards to safety were duration of hospitalization, time 
until neutrophil and platelet recovery, rate of febrile episodes, and mortality until 100 
days after ASCT, as well as the occurrence of unexpected toxicities during and after 
hospitalization for ASCT until 100 days after ASCT. Neutropenia was defined as 
neutrophil counts <0.5 G/l, and thrombocytopenia as platelet counts <20 G/l. The 
mortality until day 100 was defined as death from any cause within 100 days after 
ASCT, and TRM was defined as transplant-related death due to toxicity or infectious 
complications following ASCT.  
OS was defined as the time from ASCT until death from any cause or last follow-up. 
PFS was defined as the time from ASCT until first relapse/progression, death or last 
follow-up, whichever occurred first. Complete remission (CR) was defined as a 
negative immunofixation in serum and urine, absence of plasmocytoma and less 
than 5% plasma cells in the bone marrow. A reduction of ≥50% of serum M-protein 
was considered a partial response (PR). Progression (PD) was defined as an 
increase of at least 25% in measurable monoclonal immunoglobulin in serum or 
urine or an increase of ≥25% in urinary light chains. If CR lasted less than 3 months, 
it was defined as progression (PD). 
 
Statistical Analysis 
Survival curves were calculated using the method of Kaplan and Meier and 
compared using the log-rank test. Differences in the mean values of continuous 
variables were tested using the t-test. All statistical analyses and graphs were 
performed using graph pad prism program 7.00 (Trial Version) or Microsoft Excel 
(Microsoft Office 2016). P-values <0.05 were considered statistically significant. 
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RESULTS 
 
We identified a cohort of 298 patients with symptomatic multiple myeloma (MM) who 
received at least one high-dose chemotherapy (HDCT) with melphalan with 
autologous stem cell transplantation (ASCT) between January 2009 and May 2015 
at the University Hospital Bern, Switzerland. The patients were divided into three age 
groups: Group 1 comprised MM patients aged 18-65 years, group 2 involved MM 
patients aged 66-69 years, and MM patients in group 3 were ≥70 years. The patient 
characteristics at diagnosis are summarized in Table I. We observed that elderly MM 
patients (group 2) had more frequently advanced disease (ISS stage III) than 
younger MM patients in group 1 (59% vs. 39%; P=.0073), respectively. The 
Supplemental Table I depicts the mobilization and high dose chemotherapy 
regimens used in this study.  
Table II depicts the details on mobilization and collection of autologous stem and 
progenitor cells. All MM patients were mobilized with a single dose of non-
myelosuppressive chemotherapy using 35mg/m2 of vinorelbine or 1250mg/m2 of 
gemcitabine (but not cyclophosphamide) together with G-CSF [32-34], with a 
collection goal of at least 3x106 CD34+ cells/kg body weight (b.w.) per planned stem 
cell transplantation. Apheresis was initiated based on pre-collection peripheral 
CD34+ cell counts, and a minimum of 15 peripheral CD34+ cells/l was necessary to 
trigger the collection procedure. The minimal number of collected CD34+ cells to 
proceed to transplantation was 2x106/kg b.w.  
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254 MM patients (85%) achieved the pre-defined collection goal in a single 
apheresis day procedure, whereas 44 patients (15%) needed two days. Whereas we 
observed no differences between the three age groups in the number of apheresis 
days needed (two days of apheresis in 14%, 20%, and 17% in groups 1, 2 and 3, 
respectively, P =.455), we found that elderly patients mobilized significantly less 
circulating peripheral CD34+ cells at the day of stem cell collection (110x106/l, 
77x106/l and 50x106/l in groups 1, 2 and 3, respectively, P =.0097). Also, the 
percentage of circulating CD34+ cells per peripheral leukocytes at the day of stem 
cell collection was lower in elderly MM patients (0.5%, 0.29%, and 0.26% in groups 
1, 2 and 3, respectively, P =.2914). Due to a longer duration of stem cell collection in 
elderly patients (details not shown), the total number of collected CD34+ cells was 
comparable in all three age groups. Accordingly, the total number of re-transfused 
autologous stem cells was similar in all three age groups (Table II). 
All MM patients in this cohort received melphalan conditioning as planned: Patients 
above 70 years were given a reduced dose of melphalan 140mg/m2, whereas 
melphalan 200mg/m2 was administered in patients younger than 70 years. The 
melphalan dose was reduced to 140 mg/m2 for patients with reduced renal function 
with a creatinine-clearance between 40-50ml/min, and to 100mg/m2 for patients with 
a creatinine-clearance of below 40ml/min.  
We observed that age ≥70 years (group 3) was associated with prolonged 
hospitalization for HDCT with ASCT compared to the age groups 1 and 2 (26 days in 
group 3 vs. 19 and 20 days in groups 1 and 2; P =.0.001). We also found differences 
for the time needed until hematologic recovery (Table III). Age ≥70 years (group 3) 
was associated with a prolonged duration until recovery of platelets above 20G/L (20 
days in group 3 vs. 13 days in groups 1 and 2; P =.007). In contrast, no differences 
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were seen between the three age groups in the duration of neutropenia (12, 11 and 
11 days in groups 1, 2 and 3, P = .0751).  
A total of 44 patients have died since ASCT (15%). Four (1%) patients – all aged 
below 66 years - died within 100 days after ASCT, and all four (1%) deaths were due 
to transplant-related causes (TRM) comprising one patient dying because of septic 
shock and three patients dying because of respiratory tract infections with respiratory 
failure (Table III). TRM was not different among the three age cohorts (2% in group 1 
and 0% in groups 2 and 3; P =.5935).  
The number of febrile episodes and the number of febrile episodes with identification 
of a causing germ was similar between the three age groups, both during 
hospitalization as well as after discharge until 100 days after ASCT. Similarly, no 
differences were observed for the rate of severe complications and/or additional 
hospitalizations after discharge from HDCT/ASCT treatment between the three 
cohorts (13%, 22%, and 17%; P=.2016).   
Before ASCT, the rate of patients in CR after induction treatment was comparable 
between the three age groups (Supplemental Table II). Similarly, we observed no 
differences in the rate of achieved complete remissions (CR1) 100 days after ASCT 
(47%, 45%, and 58% in groups 1, 2 and 3; P =.7018). After a mean follow-up of 21 
months after ASCT, 114 myeloma patients (38%) in our cohort had a relapse, and 
the relapse rate was not higher in older patients (42%, 20%, and 33%; P=.0151), and 
the median duration until first relapse was similar in all three age groups (22, 18 and 
8 months in group 1,2 and 3; P=.121). We observed no differences in the PFS 
between the three age groups (Figure 1).  
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Finally, 44 deaths (15%) were reported in our cohort, with age above 65 years not 
being associated with increased death rate (18%, 2%, and 0% in group 1, 2 and 3; 
P=.0052). The OS was not inferior for elderly myeloma patients compared to patients 
below 66 years (Figure 1 and Supplemental Table II). As expected, the failure to 
achieve CR within 100 days after ASCT was associated with a less favorable PFS 
and OS (P=.0001) (Supplemental Figure 1A and 1B). For patients achieving a CR 
after ASCT, PFS and OS for patients above 65 years were comparable to younger 
myeloma patients (Supplemental Figure 1C and 1D). These data suggest that 
elderly fit myeloma patients experience similar survival benefits from HDCT with 
ASCT as myeloma patients below 66 years. 
11 
Stettler et al      Autologous transplant in elderly myeloma patients. 
DISCUSSION 
 
Few studies are available which incorporated consolidation with ASCT into the 
treatment algorithm for elderly symptomatic myeloma patients in the era of novel 
agents. Two phase II trials have consolidated the induction treatment - with four 
cycles of bortezomib, pegylated liposomal doxorubicin and dexamethasone - with 
tandem ASCT (each 100mg/m2 of melphalan), followed by consolidation therapy 
with four cycles of lenalidomide and prednisone, and a maintenance therapy with 
lenalidomide alone in patients aged 65-75 years [35,36]. The median PFS was 48 
months, and the 5-year overall survival (OS) was 63%; notably, patients achieving a 
CR had a 5-year OS of 83%. The treatment-related mortality associated with ASCT 
in these two trials was significantly higher in MM patients ≥70 years (19%) compared 
with that of MM patients (4%) less than 70 years (P= 0.024); thus, one might 
conclude that a sequential approach including reduced-intensity ASCT may benefit 
patients younger than 70 years of age with good performance status and without 
comorbidities [37-39]. In line with these reports we found in our retrospective single-
center cohort not a single treatment-related death during the 100 days after ASCT in 
71 MM patients aged between 66 and 69 years. However, we also observed no 
treatment-related death in a (small) cohort of 20 myeloma patients aged ≥70 years at 
ASCT. Our data therefore point to the possibility that age adapted high-dose 
melphalan with ASCT can be safely applied to consolidate induction treatment with 
novel agents in elderly fit myeloma patients, including myeloma patients above the 
age of 70 years. 
Importantly, we followed a strategy of applying 200mg/m2 melphalan before ASCT in 
myeloma patients below 70 years, and we reduced melphalan to 140mg/m2 for 
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patients ≥70 years. In addition, dose reductions were performed for patients with 
reduced renal function. The transplant-related mortality (TRM) for melphalan 200 
mg/m2 in elderly myeloma patients was reported to be up to 19% (17), while that for 
100 mg/m2 of melphalan was 0% (19) and 2% for 140 mg/m2 melphalan (20). Our 
single-center results with a TRM of 0% in 71 myeloma patients aged 66-69 years 
treated with 200mg/m2 melphalan challenge the need for dose reductions in 
myeloma patients in this age cohort considered to be fit for high-dose consolidation. 
In addition, we did not observe differences in the duration of hospitalization, 
hematologic recovery, number of febrile episodes or of re-hospitalizations in 
myeloma patients aged 66-69 years compared to patients below 66 years. 
Therefore, our data suggest that 200mg/m2 melphalan can be safely applied by an 
experienced transplant team to myeloma patients between 66-69 years within an 
experienced transplant team. 
We applied a reduced dose of 140mg/m2 melphalan to myeloma patients ≥70 years 
in this study. We observed few, but notable differences compared to 200mg/m2 
melphalan in patients below 70 years. The duration of hospitalization was 
significantly longer in patients ≥70 years (26 vs. 20 days), and the time until platelet 
(but not neutrophil) recovery above 20 G/L was longer (19 vs. 15 days). Since we did 
not observe more admissions to the intensive care unit, febrile episodes, or bleeding 
events, we concluded that the prolonged hospitalization of patients ≥70 years was 
related to a generally slower recovery from the deterioration of the general condition 
associated with high-dose chemotherapy. 
We observed similar rates of complete remission 100 days after ASCT in patients 
below 66 years and patients ≥66 years. Also, the progression-free survival and the 
overall survival was not different between the three age groups in this study. Thus, 
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these results suggest that elderly myeloma patients may equally benefit from 
consolidation treatment with HDCT and ASCT as younger myeloma patients in the 
era of novel agents. However, the obvious limitations of this study need to be stated 
including the retrospective, non-randomized, single-center design and the limited 
number of patients in the two elderly myeloma subgroups, as well as the limited 
follow-up. 
 
CONCLUSION 
Our data suggest that consolidation with HDCT and ASCT is feasible, safe and 
effective in myeloma patients older than 65 years. Age above 65 years, but also age 
above 70 years should not per se exclude patients from treatment with HDCT and 
ASCT. Therefore, the consolidation with HDCT and ASCT should be considered in 
elderly fit myeloma patients based on performance status and presence of 
complications and/or comorbidities, but not on chronological age alone. The 
sequential approach of MM treatment including ASCT can be challenging, but 
represents a feasible approach to further improve the outcome of elderly patients 
with multiple myeloma. 
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FIGURE LEGEND 
 
Figure 1: Depicted are Kaplan-Meier survival curves for the entire cohort of all 298 
multiple myeloma patients for (A) progression free survival and (B) overall survival, 
as well as according to the three age groups for (C) progression free survival and (D) 
overall survival. 
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